Two Indian Drug Makers Make Acquisition Moves Abroad
This article was originally published in PharmAsia News
Executive Summary
Two more Indian drug makers have moved to buy at least part of foreign firms as the industry continues acquiring other assets. Dr. Reddy's Laboratories said it would buy the U.S. pharmaceutical contract manufacturing business of BASF, but did not disclose what it would be paying. Strides Arcolab said it would buy a larger stake in Genepharm Australasia, enough to give it 55 percent ownership of the Australian firm. In return for its equity stake, Strides said it would sell Genepharm its other Australian and Asian interests for $57.3 million. (Click here for more
You may also be interested in...
GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets
MUMBAI - British drug maker GlaxoSmithKline has announced a comprehensive product licensing deal, in what it calls a "transformational agreement" with Onco Therapies - a joint venture between South Africa's largest drug firm Aspen Pharmacare and one of India's largest generic drug exporters Strides Arcolab
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Need a specific report? 1000+ reports available
Buy Reports